Collegium Pharmaceutical, Inc. COLL Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s business combination contingent consideration arrangements change in amount of contingent consideration liability1.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s business combination contingent consideration arrangements change in amount of contingent consideration liability1?
- Collegium Pharmaceutical, Inc. (COLL) reported business combination contingent consideration arrangements change in amount of contingent consideration liability1 of $0 in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s business combination contingent consideration arrangements change in amount of contingent consideration liability1 changed year-over-year?
- Collegium Pharmaceutical, Inc.'s business combination contingent consideration arrangements change in amount of contingent consideration liability1 increased by 100.0% year-over-year, from -$786K to $0.
- What does business combination contingent consideration arrangements change in amount of contingent consideration liability1 mean?
- This metric represents the periodic change in the fair value of liabilities associated with contingent consideration arrangements from business acquisitions. It reflects adjustments based on updated expectations regarding the achievement of performance milestones or financial targets that trigger additional payments to sellers. Investors monitor this to assess the impact of acquisition-related earn-outs on net income and to evaluate the accuracy of initial valuation assumptions.